MTOR and diffuse large B-cell lymphoma: MYD88 is frequently mutated in the C5/MCD DLBCL subtypes, with about 50% of the patients harboring the MYD88 L265P mutation.58, 81, 144 MYD88 forms a multiprotein supercomplex in CD79B/MYD88‐mutant cells along with TLR9 and the BCR on endolysosomes (Figure 4).145 This “My‐T‐BCR” supercomplex co‐localizes with mTOR, driving pro‐survival NF‐κB and mTOR signaling.